Literature DB >> 33394524

Nasopharyngeal swab-induced pain for SARS-CoV-2 screening: a randomised controlled trial of conventional and self-swabbing.

X Moisset1, N Gautier1, T Godet1, S Parabère1, B Pereira1, E Meunier1, L Gerbaud1, O Lesens1, C Henquell1, J Beytout1, P Clavelou1.   

Abstract

BACKGROUND: Massive screening campaigns for SARS-CoV-2 are currently carried out throughout the world, relying on reverse-transcriptase-polymerase chain reaction (RT-PCR) following nasopharyngeal swabbing performed by a healthcare professional. Yet, due to the apprehension of pain induced by nasopharyngeal probing, poor adhesion to those screening campaigns can be observed. To enhance voluntary participation and to avoid unnecessary exposition to SARS-CoV-2, self-swabbing could be proposed. To date, no data have been published concerning pain induced by conventional- or self-swabbing. Thus, the primary objective of the present study was to evaluate pain induced with the conventional swabbing method and compare it to self-swabbing. Secondary objectives focused on swabbing-induced discomfort and acceptability of the two methods.
METHODS: The study was conducted in Clermont-Ferrand medical school (France). Overall, 190 students were randomised into 2 groups and experienced either self- or conventional-swabbing. Each subject had to rate pain, discomfort and acceptability of such swabbing on a 0-10 numeric rating scale.
RESULTS: No significant difference was found between the two methods. Mean pain level was 2.5±1.9, 28% rating pain as ≥4/10. Discomfort was 4.8±2.2, 66% indicating significant (≥4/10) discomfort. Higher pain and discomfort were associated with female sex. Acceptability was ≥8/10 for 89.0% of the subjects and all would have accepted to undergo a new test with the same technique if necessary.
CONCLUSION: Both conventional and self-swabbing induce low levels of pain for most young healthy volunteers whereas discomfort is very frequent. Nonetheless, both methods are indifferently well-accepted in medical students. Future studies among symptomatic subjects are awaited. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2021        PMID: 33394524     DOI: 10.1002/ejp.1722

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  10 in total

1.  Aerosol-jet-printed graphene electrochemical immunosensors for rapid and label-free detection of SARS-CoV-2 in saliva.

Authors:  Cícero C Pola; Sonal V Rangnekar; Robert Sheets; Beata M Szydlowska; Julia R Downing; Kshama W Parate; Shay G Wallace; Daphne Tsai; Mark C Hersam; Carmen L Gomes; Jonathan C Claussen
Journal:  2d Mater       Date:  2022-06-10       Impact factor: 6.861

2.  Nasopharyngeal swabs vs. saliva sampling for SARS-CoV-2 detection: A cross-sectional survey of acceptability for caregivers and children after experiencing both methods.

Authors:  François Gagnon; Maala Bhatt; Roger Zemek; Richard J Webster; Stephanie Johnson-Obaseki; Stuart Harman
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Performance evaluation of a non-invasive one-step multiplex RT-qPCR assay for detection of SARS-CoV-2 direct from saliva.

Authors:  Chris Denning; Andrew V Benest; Claire Seedhouse; Harry H Jenkins; Ana A Tellechea Lopez; Francesco Saverio Tarantini; Hannah Tomlin; Danielle Scales; I-Ning Lee; Siyu Wu; Ralph Hyde; Katarzyna Lis-Slimak; Timothy Byaruhanga; Jamie L Thompson; Sara Pijuan-Galito; Lara Doolan; Kazuyo Kaneko; Penny Gwynne; Caroline Reffin; Emily Park; Jayasree Dey; Jack Hill; Asta Arendt-Tranholm; Amy Stroud; Moira Petrie
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

4.  Supporting COVID-19 School Safety for Children With Disabilities and Medical Complexity.

Authors:  Michael R Sherby; Luther G Kalb; Ryan J Coller; Gregory P DeMuri; Sabrina Butteris; John J Foxe; Martin S Zand; Edward G Freedman; Stephen Dewhurst; Jason G Newland; Christina A Gurnett
Journal:  Pediatrics       Date:  2022-02-01       Impact factor: 9.703

5.  Detection of SARS-CoV-2 by rapid antigen tests on saliva in hospitalized patients with COVID-19.

Authors:  Yang De Marinis; Anne-Katrine Pesola; Anna Söderlund Strand; Astrid Norman; Gustav Pernow; Markus Aldén; Runtao Yang; Magnus Rasmussen
Journal:  Infect Ecol Epidemiol       Date:  2021-10-29

6.  Insight into pain syndromes in acute phase of mild-to-moderate COVID-19: Frequency, clinical characteristics, and associated factors.

Authors:  Emel Oguz-Akarsu; Gizem Gullu; Erhan Kilic; Yasemin Dinç; Ahmet Ursavas; Emel Yilmaz; Mehmet Zarifoglu; Necdet Karli
Journal:  Eur J Pain       Date:  2021-10-26       Impact factor: 3.651

7.  Acceptability of OP/Na swabbing for SARS-CoV-2: a prospective observational cohort surveillance study in Western Australian schools.

Authors:  Hannah M Thomas; Marianne J Mullane; Sherlynn Ang; Tina Barrow; Adele Leahy; Alexandra Whelan; Karen Lombardi; Matthew Cooper; Paul G Stevenson; Leanne Lester; Andrea Padley; Lynn Sprigg; David Speers; Adam J Merritt; Juli Coffin; Donna Cross; Peter Gething; Asha C Bowen
Journal:  BMJ Open       Date:  2022-01-26       Impact factor: 2.692

8.  Performance of saliva compared with nasopharyngeal swab for diagnosis of COVID-19 by NAAT in cross-sectional studies: Systematic review and meta-analysis.

Authors:  Donald Brody Duncan; Katharine Mackett; Muhammad Usman Ali; Deborah Yamamura; Cynthia Balion
Journal:  Clin Biochem       Date:  2022-08-08       Impact factor: 3.625

9.  Preclinical Validation of a Novel Injection-Molded Swab for the Molecular Assay Detection of SARS-CoV-2.

Authors:  Chiara E Ghezzi; Devon R Hartigan; Justin P Hardick; Rebecca Gore; Miryam Adelfio; Anyelo R Diaz; Pamela D McGuinness; Matthew L Robinson; Bryan O Buchholz; Yukari C Manabe
Journal:  Diagnostics (Basel)       Date:  2022-01-15

10.  How to make universal, voluntary testing for COVID-19 work? A behavioural economics perspective.

Authors:  Francesco Fallucchi; Luise Görges; Joël Machado; Arne Pieters; Marc Suhrcke
Journal:  Health Policy       Date:  2021-05-16       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.